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Edited by Hans-Dieter KlenkAbstract Severe acute respiratory syndrome (SARS) has
become a global public health emergency. p38 mitogen-activated
protein kinase (MAPK) and its downstream targets are activated
in SARS coronavirus (SARS-CoV)-infected Vero E6 cells and
activation of p38 MAPK enhances the cytopathic eﬀects of
SARS-CoV infection. In addition, weak activation of Akt cannot
prevent SARS-CoV infection-induced apoptosis in Vero E6 cells.
In the present study, we demonstrated that signal transducer and
activator of transcription (STAT) 3, which is constitutively
phosphorylated at tyrosine (Tyr)-705 and slightly phosphory-
lated at serine (Ser)-727 in Vero E6 cells, was dephosphorylated
at Tyr-705 on SARS-CoV infection. In addition to phosphory-
lation of p38 MAPK in virus-infected cells, other MAPKs, i.e.,
extracellular signal-regulated kinase (ERK) 1/2 and c-Jun N-
terminal kinase (JNK), were phosphorylated. Although inhibi-
tors of ERK1/2 and JNK (PD98059 and SP600125) had no
eﬀect on phosphorylation status of STAT3, inhibitors of p38
MAPK (SB203580 and SB202190) partially inhibited dephos-
phorylation of STAT3 at Tyr-705. Tyr-705-phosphorylated
STAT3 was localized mainly in the nucleus in mock infected
cells, whereas STAT3 disappeared from the nucleus in virus-
infected cells. As STAT3 acts as an activator of transcription in
the nucleus, these results suggest that STAT3 lacks its activity
on transcription in SARS-CoV-infected Vero E6 cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Severe acute respiratory syndrome (SARS) is a newly found
infectious disease caused by a novel coronavirus, SARS co-
ronavirus (SARS-CoV) [1,2]. In late 2002, SARS-CoV spread
from Guangdong Province in China to more than 30 countries.
The pathogenesis of SARS in vivo may be mediated by both
the eﬀect of viral replication in the target cells and immune
responses. Recently, we reported that p38 mitogen-activated* Corresponding author. Fax: +81-42-564-4881.
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doi:10.1016/j.febslet.2004.10.005protein kinase (MAPK) plays important roles in the cytopathic
eﬀects and apoptosis in SARS-CoV-infected cells [3]. Fur-
thermore, weak activation of Akt cannot prevent apoptosis by
SARS-CoV-infection [4]. Thus, it is necessary to examine the
signaling pathways in SARS-CoV-infected cells in culture to
understand the molecular mechanisms of its pathology in vivo.
MAPKs are signal transducers that respond to extracellular
stimulation by cytokines, growth factors, viral infection, and
stressors, and in turn regulate cell diﬀerentiation, proliferation,
survival, and apoptosis [5–8]. p38 MAPK is strongly activated
by stressors and inﬂammatory cytokines. Our previous study
indicated that p38 MAPK phosphorylation in SARS-CoV-
infected Vero E6 cells reached the maximal level at 18 h post-
infection (h.p.i.) and cytopathic eﬀects (CPEs) were observed
from 24 h.p.i. [3]. The CPEs were partially prevented by
treatment with the p38 MAPK inhibitor SB203580, strongly
suggesting that the p38 MAPK signaling pathway is involved
in the control of cell death in SARS-CoV-infected Vero E6
cells. On the other hand, signal transducer and activator of
transcription (STAT) proteins are transcription factors that
mediate cytokines and growth factors. Activation of all STAT
proteins is induced by phosphorylation of a single tyrosine
residue, leading to dimerization via an intermolecular SH2
phosphotyrosine interaction [9–12]. STAT3 is a major tran-
scription factor activated in response to cytokines, such as
interleukin-6 (IL-6) and IL-10. Inhibition of STAT3 signaling
by dominant negative and antisense STAT3 inhibitors resulted
in a decrease in cell viability and subsequent apoptosis [13–15].
Thus, STAT3 is thought to act as an anti-apoptotic tran-
scription factor. Recent studies indicated that interactions
between STATs and some viral proteins cause degradation of
STATs in virus-infected cells. For example, V protein of
measles virus forms complexes with STAT1, STAT2, and
STAT3, and inhibits extracellular (IL-6) and intracellular (v-
Src) STAT3-dependent signaling [16]. Thus, measles virus-in-
duced degradation of STATs may provide a mechanism for
virus-induced cytokine inhibition that links innate immune
evasion to adaptive immune suppression.
In the present study, we found that STAT3, constitutively
phosphorylated at tyrosine (Tyr)-705 and slightly phosphory-
lated at serine (Ser)-727 in Vero E6 cells, was dephosphoryl-
ated at Tyr-705 by activation of p38 MAPK on SARS-CoV
infection. Lack of transcriptional activity of STAT3 by viral
infection may decrease anti-apoptotic activity in the cells.blished by Elsevier B.V. All rights reserved.
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2.1. Cells and virus
Vero E6 cells were routinely subcultured in 75-cm3 ﬂasks in Dul-
becco’s modiﬁed Eagle’s medium (DMEM, Sigma, St. Louis, MO,
USA) supplemented with 0.2 mM L-glutamine, 100 units/ml penicillin,
100 lg/ml streptomycin, and 5% (v/v) fetal bovine serum (FBS), and
maintained at 37 C in an atmosphere of 5% CO2. For use in the ex-
periments, the cells were split once onto 6- or 24-well tissue culture
plate inserts and cultured until they reached 100% conﬂuence. The
culture medium was changed to 2% FBS containing DMEM prior to
virus infection. SARS-CoV, which was isolated as Frankfurt 1 [17] and
kindly provided by Dr. J. Ziebuhr, was used in the present study. In-
fection was usually performed with a multiplicity of infection (m.o.i.)
of 10.
2.2. Treatment with inhibitors
SB203580 and SB202190 as p38 MAPK inhibitors, PD098059 as a
MEK inhibitor and SP600125 as a JNK inhibitor were dissolved in
dimethyl sulfoxide (DMSO) at a concentration of 10 or 20 mM. All
reagents were purchased from Calbiochem (San Diego, CA, USA). All
test wells, including mock treated controls, were treated with 0.25%
DMSO (v/v). Vero E6 cells were inoculated with SARS-CoV at m.o.i.
of 10 for 1 h and then cells were treated with inhibitors for 17 h.
2.3. Subcellular fractionation
SARS-CoV-infected or mock infected Vero E6 cells at 18 h.p.i. were
subjected to subcellular fractionation using a Subcellular Proteome
Extraction Kit (Calbiochem) according to the manufacturer’s in-
structions. Each subcellular fraction was then analyzed by Western
blotting.
2.4. Western blotting
After virus infection, whole-cell extracts were electrophoresed on
either 12.5% or 10–20% gradient polyacrylamide gels and transferred
onto PVDF membranes (Immobilon-P, Millipore, Bedford, MA,
USA). In the present study, we applied two sets of samples to poly-
acrylamide gels and the membranes were divided into two halves after
blotting. The following antibodies, obtained from Cell Signaling
Technology Inc. (Beverly, MA, USA), were used in the present study
at a dilution of 1:1000: rabbit anti-phospho STAT3 (Tyr-705) anti-
body, rabbit anti-phospho STAT3 (Ser-727) antibody, rabbit anti-p38
MAPK (Thr180/Tyr182) antibody, rabbit anti-p38 MAPK antibody,
rabbit anti-phospho p44/42 MAPK (Thr202/Tyr204) (¼ERK1/2)
antibody, rabbit anti-p44/42 MAPK (¼ERK1/2) antibody, rabbit
anti-phospho SAPK/JNK (Thr183/Tyr185) antibody, anti-SAPK/
JNK antibody, anti-phospho MEK1/2 (Ser217/221) antibody, anti-
MEK1/2 antibody, anti-phospho SEK1/MKK4 (Thr261) antibody,
anti-SEK1/MKK4 antibody, anti-phospho MKK7 (Ser271/Thr275)
antibody, anti-MKK7 antibody, anti-phospho MKK3/MKK6
(Ser189/207) antibody, anti-MKK3 antibody, anti-phospho Jak1
(Tyr1022/1023) an- tibody, anti-phospho JAK2 (Tyr1007/1008) anti-
body, and anti-phospho Tyk2 (Tyr1054/1055) antibody. Mouse anti-
STAT3 antibody (diluted 1:2500), mouse anti-JAK1 antibody (diluted
1:250), and mouse anti-Tyk2 antibody (diluted 1:1000), obtained from
BD Biosciences, Franklin Lakes, NJ, USA, were also used. Rabbit
anti-JAK2 antibody (C-20, diluted 1:200) was obtained from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). After 15-h incubation
with the above antibodies, the membranes were washed with Tris-
borate saline containing 0.1% Tween 20 (0.1% TBS–Tween) and the
reactions were detected with a ProtoBlot II AP system (Promega Co.,
Madison, WI, USA), as described previously [18].Fig. 1. Infection of Vero E6 cells with SARS-CoV aﬀected the signaling
pathway of STAT3. Western blotting analysis of proteins from SARS-
CoV-infected Vero E6 cells was performed using antibodies that rec-
ognized forms of STAT3 phosphorylated at Tyr-705 or Ser-727.3. Results
3.1. Tyrosine dephosphorylation of STAT3 in
SARS-CoV-infected cells
As described in our previous report, we compared the cel-
lular protein proﬁles of SARS-CoV-infected (18 h.p.i. when
apoptosis was not evident) and mock infected Vero E6 cells by
Western blotting using 125 antibodies to investigate cellular
responses to SARS-CoV-infection [3,4]. Cellular proteins re-lated to several signaling pathways that responded speciﬁcally
to SARS-CoV infection, including p38 MAPK and Akt, were
found. In the present study, we examined whether signal
transducer and activator of transcription 3 (STAT3) was
dysregulated on infection with SARS-CoV, as reported for
measles virus-infection [16]. Vero E6 cells were infected with
SARS-CoV at m.o.i. of 10, and cellular proteins were har-
vested at 6, 12, 18, and 24 h.p.i. Western blotting analysis was
performed using a series of anti-STAT3 antibodies that rec-
ognized total STAT3 or Tyr-705- or Ser-727-phosphorylated
forms of STAT3. In Vero E6 cells, STAT3 was phosphorylated
constitutively at Tyr-705, whereas Ser-727 was only slightly
phosphorylated (Fig. 1; mock infection). Constitutive activa-
tion of STAT3 was observed in breast carcinoma cell lines [19].
Interestingly, Tyr-705-phosphorylated STAT3 was not de-
tected after 18 h.p.i. in SARS-CoV-infected Vero E6 cells, even
though the total amount of STAT3 did not change until 24
h.p.i. (Fig. 1). This result suggested that STAT3 Tyr-705 was
dephosphorylated from 18 to 24 h.p.i. On the other hand, Ser-
727-phosphorylated STAT3 was slightly increased at the same
time points. Based on the hypothesis that tyrosine phosphor-
ylation of STAT is necessary for its activation [9–12], these
results suggest that the level of activation of STAT3 was de-
creased in SARS-CoV-infected Vero E6 cells. Thus, the
mechanism of dysregulation of STAT3 by SARS-CoV is dif-
ferent from that by measles virus in which Measles virus V
protein forms complexes with STATs resulting in degradation
of STAT3.
3.2. Phosphorylation level of upstream kinases of STAT3
As a general explanation of signal transduction of STAT3,
binding of IL-6 to the receptor induces dimerization of the
common gp130 signal transduction subunit of the IL-6 family
of cytokine receptors, and then Janus kinases (JAK1 and 2)
and Tyk2 are phosphorylated at tyrosine residues through a
conserved membrane-proximal binding domain [20]. The
phosphorylated JAKs and Tyk2 create docking sites for
STAT3. Dimeric STAT3 Tyr-phosphorylated by JAKs and
Tyk2 migrates to the nucleus, where STAT3 activates tran-
scription of speciﬁc genes. Thus, JAK1, JAK2, Tyk2, and
STAT3 are phosphorylated in response to IL-6. To test the
hypothesis that Tyr-705-dephosphorylation of STAT3 by
SARS-CoV infection occurred due to a lack of signals from
JAK1/2 and Tyk2, the phosphorylation status of these kinases
was examined in virus-infected or mock infected Vero E6 cells.
As shown in Fig. 2, JAK1, JAK2, and Tyk2 were phosphor-
Fig. 3. Subcellular localization of Tyr-phosphorylated STAT3. (A)
Vero E6 cells were incubated in DMEM containing 0%, 2% or 5% FCS
for 18 h. After subcellular fractionation, Western blotting was per-
formed using anti-phospho STAT3 (Tyr) antibody. (B) C, M, N, S,
and T indicate cytosolic, organelle/membrane, nuclear, cytoskeletal,
and total cellular fraction, respectively.
Fig. 4. IL-22 induces Tyr phosphorylation of STAT3. (A) Vero E6 cells
were treated with IL-22 from 0 to 90 min. Cellular proteins were
sampled every 15 min. Western blotting was performed using anti-
phospho STAT3 (Tyr and Ser) antibodies. (B) SARS-CoV-infected
Vero E6 cells were treated with IL-22 for 20 min at 18 h.p.i., and then,
Western blot analysis was performed using anti-phospho STAT3 (Tyr)
and anti-phospho p38 MAPK.
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cant changes in phosphorylation level of these kinases were
observed after virus infection. These observations suggest that
Tyr-705 dephosphorylation of STAT3 in virus-infected cells
occurred independent of its upstream kinases. Therefore, total
activity of STAT3 may be low in Vero E6 cells. However, it
can not be ruled out that the anti-phospho JAK1, JAK2 and
Tyk2 antibodies used in the present study are diﬃcult to be
recognized in the phosphorylated JAK1, JAK2 and Tyk2 in
Vero E6 cells as the datasheet included no description of cross-
reactivity with monkey.
3.3. Stimulation of Tyr-705 phosphorylation of STAT3 by
cytokines
Previous studies have indicated that at least six cytokines,
IL-2, IL-6, IL-10, IL-15, IL-17, and IL-22, can stimulate ac-
tivation of STAT3 [21–24]. Tyr-705 dephosphorylation of
STAT3 in virus-infected cells may be due to a lack of stimu-
lation by these cytokines after 18 h.p.i. Therefore, it is im-
portant to identify the cytokines responsible for stimulating
Tyr phosphorylation of STAT3 to understand the mechanism
of Tyr-705-dephosphorylation of STAT3 in virus-infected
cells. To investigate whether fetal calf serum (FCS) in the
medium contains stimulators for STAT3 phosphorylation,
Vero E6 cells were cultured in DMEM containing 0%, 2% or
5% FCS for 18 h, subjected to subcellular fractionation, and
then the proteins were analyzed by Western blotting using
anti-phospho-speciﬁc antibodies. As shown in Fig. 3A, there
were no signiﬁcant diﬀerences in total amount of STAT3 in
cultures with various concentrations of FCS in the medium.
This result suggests that FCS does not contain components
that stimulate Tyr-phosphorylation of STAT3. We next de-
termined cytokines and their receptors produced in Vero E6
cells using a GEArray Q Series Human Interleukin and Re-
ceptor Gene Array (SuperArray Bioscience Corporation,
Frederick, MD, USA). Expression level of IL-22, which has
also been reported as a stimulator of STAT3 [23], was very
low, and receptors for IL-22 (IL-22RA1 and RA2) were ob-
tained as strong and weak signals, respectively (data not
shown). Therefore, we examined whether IL-22 stimulated
Tyr-705 and Ser-727 phosphorylation of STAT3. As shown in
Fig. 4A, the level of Tyr-705-phosphorylated STAT3 increased
15 min after treatment with murine IL-22 (200 ng/ml) (Pepro
Tech EC, London, UK), whereas phosphorylation of Ser-727
was not enhanced, suggesting that it is diﬃcult for Ser-727 ofFig. 2. Phosphorylation levels of upstream kinases of STAT3 in virus-
infected cells. Western blotting analyses were performed using anti-
phospho JAK1, JAK2, and Tyk2 antibodies.STAT3 to be phosphorylated in Vero E6 cells stimulated by
SARS-CoV infection and IL-22. Although the phosphoryla-
tion level of p38 MAPK was not changed in SARS-CoV-in-
fected Vero E6 cells by treatment with IL-22 for 20 min at 18
h.p.i., the Tyr-705-phosphorylation of STAT3 increased
(Fig. 4B). These results suggest that signaling pathway via IL-
22 is not regulated by p38 MAPK in Vero E6 cells.
3.4. Tyr-705-phosphorylated STAT3 in the nucleus
To determine the localization of Tyr-705-phosphorylated
STAT3 in Vero E6 cells, subcellular extraction was performed
using a Subcellular Proteome Extraction Kit (Calbiochem) and
then Western blotting analyses were performed. As described
above, the amounts of total and Tyr-705-phosphorylated
STAT3 were similar in cells grown in media containing 0%, 2%
or 5% FCS. The subcellular localization of STAT3 was not
190 T. Mizutani et al. / FEBS Letters 577 (2004) 187–192aﬀected by the concentration of FCS (Fig. 3A). Total STAT3
was located mainly in the cytosol, and also in membranes/or-
ganelles and the nuclear fractions. On the other hand, Tyr-
705-phosphorylated STAT3 appeared mainly in the nuclear
fraction. We next examined whether Tyr-705-phosphorylated
STAT3 was not present in the nucleus in SARS-CoV-infected
Vero E6 cells at 18 h.p.i. As shown in Fig. 3B, Tyr-705-
phosphorylated STAT3 had clearly disappeared from the
nuclear fraction in virus-infected cells. This result strongly
suggested that STAT3 did not act as a transcriptional enhancer
in SARS-CoV-infected Vero E6 cells after 18 h.p.i.
3.5. Phosphorylation of MAPKs in SARS-CoV-infected cells
Our previous report indicated that SARS-CoV-infection to
Vero E6 induced phosphorylation of p38 MAPK and its
downstream targets, HSP-27, eIF4E and CREB [3]. Phos-
phorylation of these proteins was prevented by treatment of
the cells with the p38 MAPK inhibitor SB20854. MAPKs were
reported to induce Ser-727 phosphorylation of STAT3 [25]. To
investigate whether other MAPKs, i.e., ERK1/2 (extracellular
signal-regulated kinase) and JNK, are also phosphorylated in
SARS-CoV-infected Vero E6 cells, the kinetics of phosphor-
ylation of ERK1/2 and JNK were analyzed by Western blot-
ting. Vero E6 cells were infected with SARS-CoV at m.o.i. of
10 and the cell extracts were prepared at various time points
after infection. Western blotting analysis demonstrated that
levels of phosphorylated ERK1/2 and JNK were increased in
SARS-CoV-infected cells (Fig. 5A). Two phosphorylated
forms of ERK, ERK1 and ERK2, were detected at 12 h.p.i.
and accumulated continuously up to 24 h.p.i. The kinetics of
accumulation of phosphorylated ERK1/2 and JNK in the in-
fected cells were similar to that of accumulation of phos-
phorylated p38 MAPK. We next examined whether the
upstream MAPK kinases (MAPKKs) were also phosphory-
lated in SARS-CoV-infected Vero E6 cells. The kinases of p38,
ERK1/2, and JNK are known as MKK3/6, MEK1/2, andFig. 5. MAPKs phosphorylation in virus-infected cells. Western blot-
ting analysis of proteins from SARS-CoV-infected Vero E6 cells was
performed using anti-phospho ERK1/2, JNK, MEK1/2, MKK4,
MKK7, and MKK3/6 antibodies.MKK4/7, respectively. As shown in Fig. 5, MKK3/6, MEK1/
2, and MKK4/7 were phosphorylated in SARS-CoV-infected
Vero E6 cells.
3.6. Tyr dephosphorylation of STAT3 by p38 MAPK
To investigate whether Tyr-705 phosphorylation is regulated
by activated MAPKs in SARS-CoV-infected Vero E6 cells, the
infected cells were treated for 18 h with three MAPK inhibi-
tors: SB203580 (p38 MAPK inhibitor), PD98059 (MEK
inhibitor), and SP600125 (JNK inhibitor). Tyr-705- and Ser-
727-phosphorylated STAT3 were then analyzed by Western
blotting. As shown in Fig. 6A, SB203580 did not aﬀect Ser-727
phosphorylation of STAT3, while SARS-CoV-induced de-
phosphorylation of STAT3 Tyr-705 was partially inhibited by
SB203580. On the other hand, neither PD98059 nor SP600125
aﬀected STAT3 phosphorylation. To conﬁrm whether inhibi-
tion of p38 prevents dephosphorylation of STAT3 Tyr-705,
virus-infected cells were treated with another p38 inhibitor,
SB202190. As shown in Fig. 6B, Tyr-705 dephosphorylation of
STAT3 in the infected cells was also partially inhibited by
SB202190. These results indicated that activated p38 MAPK in
SARS-CoV-infected Vero E6 cells regulates Tyr-705 phos-
phorylation of STAT3, but not that of Ser-727.4. Discussion
In the present and previous studies, we reported that the
cellular mechanisms by which SARS-CoV caused the activa-
tion of physiological intracellular signaling cascades that lead
to the phosphorylation and activation of downstream mole-
cules [3,4]. We showed here that SARS-CoV-infection of per-
missive Vero E6 cells stimulated p38, ERK1/2, and JNKFig. 6. Eﬀects of treatment of SARS-CoV-infected Vero E6 cells with
p38 MAPK inhibitor. (A) Vero E6 cells were infected with SARS-CoV
at m.o.i. of 10, and then incubated with SB203580, PD98059, and
SP600125 at concentrations from 10 to 50 lM for 17 h. Western
blotting analyses were performed to detect Tyr-705- and Ser-727-
phosphorylated forms of STAT3. (B) SB202190 was used as a p38
MAPK inhibitor.
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cytopathic eﬀects in Vero E6 cells, whereas ERK1/2 and JNK
had no eﬀect (unpublished data). As MAPKKs for p38,
ERK1/2, and JNK were all phosphorylated in virus-infected
cells, further studies are needed to identify triggers of the
stress-activated response pathway by viral infection. The
present study strongly suggested that the p38 MAPK signaling
pathway is upstream of Tyr-705 dephosphorylation of STAT3.
We also demonstrated that infection with SARS-CoV slightly
increased the level of phosphorylation of Ser-727 STAT3.
Although the eﬀect of Ser-727 phosphorylation on the function
of STAT3 in SARS-CoV-infected cells remains unresolved, a
previous study showed that phosphorylation of Ser-727 of
STAT3 negatively modulates its tyrosine phosphorylation [26].
Thus, the timing of Tyr-705 dephosphorylation and Ser-727
phosphorylation may be almost the same in SARS-CoV-in-
fected cells. The Ser-727-phosphorylated STAT3-mediated
expression of a Bcl-2 family member, Mcl-1, is essential for the
survival of cells [27], suggesting that Ser-727-phosphorylated
STAT3 has anti-apoptotic activity. However, the mechanism
through which serine phosphorylation regulates the tran-
scriptional activities of STAT3 is still unclear. On the other
hand, one of the important roles of Tyr-705-phosphorylated
STAT3 is binding to regulatory DNA elements that control
the expression of target genes [28,29]. Suppression of STAT3
expression by siRNA induces apoptosis in several astrocytoma
cell lines, and STAT3 is required for the expression of the anti-
apoptotic genes survivin and Bcl-xL in the A172 glioblastoma
cell line [30]. In addition, the role of STAT proteins during
viral infection has been the subject of several recent studies.
The proteasome-dependent degradation of STAT1 is induced
by V protein of simian virus 5 [31], while type II human
parainﬂuenza virus V protein targets STAT2, and mumps vi-
rus V protein targets both STAT1 and STAT3 [32–34]. In
measles virus-infected cells, the V protein forms complexes
with STAT1, STAT2, and STAT3, and inhibits both IL-6- and
v-Src STAT3-dependent signaling [16]. Thus, a role of V
protein as an inhibitor of the STAT3 signaling pathway is
advantageous for viral growth. SARS-CoV may also obtain a
growth advantage by Tyr-705 dephosphorylation of STAT3.
Our recent study indicated that Akt was also activated in
response to SARS-CoV-replication [4]. Although phosphory-
lation of serine residue 473 on Akt was detected at least 8
h.p.i., threonine residue 308 was not phosphorylated in virus-
infected Vero E6 cells. A downstream target of Akt, glycogen
synthase kinase 3b (GSK-3b), was slightly phosphorylated,
indicating that the level of activation of Akt was very low. The
present study showed that IL-22 can induce Tyr-705 phos-
phorylation of STAT3, but not Ser-727 phosphorylation,
similarly to SARS-CoV infection. It may be diﬃcult for Ser-
727 of STAT3 to be phosphorylated in Vero E6 cells, similarly
to Thr-308 of Akt. Based on these results, we hypothesized
that weak activation of Akt cannot prevent apoptosis induced
by SARS-CoV infection in Vero E6 cells. In SARS-infected
Vero E6 cells, both incomplete activation of Akt and STAT3
dephosphorylation via p38 MAPK activation lead to apopto-
tic cell death. We assume that these are at least part of the
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